GlassScriptPhysician profile
Ernesto Deleon
NPI 1124583307
$5,700.19
in general payments reported to CMS, 2019-2025
48 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $406 · 2023: $1,831 · 2024: $2,124 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,784 · Education: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,784.27 |
| Education | $509.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $557.82 | 2023-2025 | Erleada, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $535.28 | 2022-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $432.82 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $356.26 | 2022-2025 | |
| Genentech USA, INC. | $344.58 | 2023-2025 | Tecentriq, Tecentriq Hybreza, Polivy |
| Daiichi Sankyo INC. | $298.41 | 2022-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $298.10 | 2023-2024 | |
| Astellas Pharma US INC | $267.40 | 2024-2025 | Xtandi, Vyloy |
| Seagen INC. | $241.54 | 2023-2025 | Tukysa |
| Pfizer INC. | $232.00 | 2023-2025 | |
| Genzyme Corporation | $184.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $144.15 | 2023-2025 | |
| Celgene Corporation | $139.23 | 2023-2024 | Pomalyst, Reblozyl |
| Sobi, INC | $133.58 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $111.36 | 2023-2024 | Libtayo |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $110.76 | 2023-2025 | Xermelo, Zoladex |
| Pharmacosmos Therapeutics INC. | $106.60 | 2023-2024 | Monoferric, Cosela |
| Array Biopharma INC | $99.78 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $97.80 | 2022-2025 | Opdivo, Opdualag |
| Incyte Corporation | $91.91 | 2023-2025 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $87.24 | 2022-2024 | Ojjaara, Shingrix |
| Taiho Oncology, INC. | $67.23 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.35 | 2022-2024 | Vpriv |
| Genmab U.S., INC. | $56.72 | 2023-2025 | Epkinly |
| Amgen INC. | $46.68 | 2022-2023 | Kyprolis, Nplate, Xgeva |
| Abbvie INC. | $44.99 | 2024-2025 | |
| Spectrum Pharmaceuticals INC. | $43.64 | 2023-2025 | Rolvedon |
| Pharmaessentia USA Corporation | $41.27 | 2023-2024 | Besremi |
| Immunocore Limited | $40.96 | 2023 | Kimmtrak |
| Amneal Pharmaceuticals LLC | $36.14 | 2022-2023 | Neupogen, Avastin, Neulasta |
| Rigel Pharmaceuticals, INC. | $35.95 | 2023 | Rezlidhia, Tavalisse |
| Myriad Genetic Laboratories, INC. | $31.77 | 2023 | Precisetumor |
| Morphosys, US INC. | $29.76 | 2023 | Monjuvi |
| Cti Biopharma Corp. | $28.77 | 2023 | Vonjo |
| Ipsen Biopharmaceuticals, INC | $26.40 | 2023-2024 | Onivyde, Somatuline Depot |
| Jazz Pharmaceuticals INC. | $22.65 | 2023 | |
| Adaptive Biotechnologies Corporation | $22.13 | 2023 | Clonoseq |
| Octapharma USA, INC. | $20.00 | 2023 | Panzyga |
| Organon LLC | $19.75 | 2023 | Ontruzant |
| Otsuka America Pharmaceutical, INC. | $19.03 | 2024 | Rexulti |
| Servier Pharmaceuticals LLC | $18.45 | 2023 | |
| Kite Pharma, INC. | $17.80 | 2023 | |
| Deciphera Pharmaceuticals INC. | $17.60 | 2025 | Qinlock, Tgct |
| Pharming Healthcare, INC. | $17.22 | 2022 | |
| Emd Serono, INC. | $16.70 | 2023 | Bavencio |
| Macrogenics, INC. | $14.27 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2022 | |
| Iovance Biotherapeutics, INC. | $13.39 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.